Showing results (141-150 of 257) with videos related to

Sort By:
Pageof 26
Heliyon|August 22, 2024
The anti-COVID-19 drug nirmatrelvir crosses the blood‒brain barrier and exhibits herb-drug pharmacokinetic interactions with Scutellaria baicalensis formulationsWan-Hsin Lee, Yen-Ying Kung, Chung-Kai Sun, et al.
Journal of Biomedical Optics|May 26, 2023
Realization of NIR-II 3D whole-body contour and tumor blood vessels imaging in small animals using rotational stereo vision techniqueShih-Po Su, Yun-Chen Lee, Syue-Liang Lin, et al.
Biomed Research International|August 12, 2014
Cisplatin-based chemotherapy versus cetuximab in concurrent chemoradiotherapy for locally advanced head and neck cancer treatmentMing-Hung Hu, Ling-Wei Wang, Hsueh-Ju Lu, et al.
Anti-Cancer Drugs|May 31, 2008
Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patientsZyting Chu, Jen-Shi Chen, Chi-Ting Liau, et al.
Cancer Chemotherapy and Pharmacology|April 13, 2011
Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II studyPeter Mu-Hsin Chang, Cheng-Hwai Tzeng, Ming-Huang Chen, et al.
Medicine|September 25, 2015
Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan: A Nationwide Population-Based StudyYi-Ping Hung, Chia-Jen Liu, Yu-Wen Hu, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2021
Interplay between desmoglein2 and hypoxia controls metastasis in breast cancerPo-Hao Chang, Min-Che Chen, Ya-Ping Tsai, et al.
Journal of Cellular and Molecular Medicine|January 5, 2025
Integrating Ultrabright Polymer Dots and Stereo NIR-II Imager for Assessing Anti-Angiogenic Drugs in Oral Cancer ModelBo-Han Huang, Fang-Yu Li, Shih-Po Su, et al.
Cancer Medicine|July 5, 2022
A generational comparison for unfavorable cancer of unknown primary in a single institute over 20 yearsCheng-Yu Tang, Jen-Fan Hang, Yi-Ping Hung, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 28, 2019
DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulationSsu-Chuan Lai, Yu-Ting Su, Ching-Chi Chi, et al.
Pageof 26